Andy Burnham faces a lot of big decisions. But one of the incoming prime minister’s biggest early tests is what he does about the world’s “scariest company” – Palantir. The US defence and surveillance tech behemoth has a swathe of British public contracts, including, most controversially, a £330m deal with the NHS. It’s pretty clear what many of Burnham’s new parliamentary colleagues want him to do: the science, innovation and technology committee says the government should ditch Palantir and its “clear mismatch with UK values”.
Peter Thiel and Alex Karp’s company is not without British backers. The Times and the Telegraph have been enthusiastic supporters. In the Financial Times last month former Conservative party adviser Camilla Cavendish accused Palantir’s critics of putting politics over progress: “To me, what matters is what works.”
But does Palantir work for Britain? Does the £330m federated data platform (FDP) live up to the claims of Palantir and NHS England? Has it delivered the much-vaunted digital revolution in our healthcare system?
These are questions my Democracy for Sale colleague Lucas Amin and I have been investigating for the past year. We spoke to NHS whistleblowers and Palantir staff, obtained confidential documents and unearthed new data. Our findings, published in the London Review of Books, raise serious questions about the efficacy of Palantir’s technology, about the approach of NHS senior leaders and about the lobbying that helped a Silicon Valley startup expand so quickly in Britain.
Let’s start with the most important part of Palantir’s British operation: the FDP. Built on the company’s Foundry software, the platform was sold as a generational chance to knit disparate data from hospitals, doctors, pharmacists and myriad other sites together into a coherent whole. You’d struggle to find anyone in the NHS who would oppose that.
NHS England cites impressive statistics for the FDP’s rollout since it launched in 2024. It says almost two-thirds of NHS trusts are “live” on Palantir’s software. Politicians and NHS leaders have hailed the FDP as a success. But drill a little deeper and you’ll find another story. Dozens of the trusts that NHS England says are using the FDP appear not to have logged into a single FDP app in the past year, according to internal usage data released under the Freedom of Information Act.
The Cancer 360 tool, which Keir Starmer lauded last year as “groundbreaking new technology” that would “slash treatment delays across the NHS”, was used by just six out of about 200 trusts in the nine months since it launched. (Palantir told us that the firm is merely a software provider: “How that software is used is controlled by the NHS trusts who use it.”)
Clinicians’ reluctance around using Palantir’s software is less ideological – although some object on this basis, too – and more practical: many trusts say that the FDP is slower and less…
Source link
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We blogs.grocliq.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at [email protected]
